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Abstract 
The field of stem cell research has been growing more because of the interest in 
using stem cells to cure diseases and heal injuries. Human embryonic stem cells, because of 
the controversy surrounding them—and subsequently the difficulties in acquiring samples 
of the existing aging cell lines—can only be used in limited capacities. While the 
development of induced pluripotent stem cells in the last decade has allowed the field to 
progress closer to medical treatments, the low efficiency of reprogramming a somatic cell 
to a pluripotent state, and the vast molecular and genomic differences between human 
embryonic stem cells and human induced pluripotent stem cells is still an issue. Therefore, 
the goal is to discover methods, chemicals, and factors that can reduce these differences 
and increase the efficiency of inducing pluripotency. 
This proposal aims to look at the effects of the protein ECAT1 in inducing 
pluripotency in human somatic cells. Little is known about ECAT1, otherwise known as 
Embryonic Stem Cell-Associated Transcript 1, beyond its presence in human embryonic 
stem cells and oocytes and its absence in differentiated cells. While originally considered by 
scientists during the development of the reprogramming technique, ECAT1's effects have 
not been tested in humans. Therefore, a series of experiments will be performed in which 
ECAT1 will be used in conjunction with OSKM to induce pluripotency in adult human dermal 
fibroblasts, which will then be differentiated into spinal motor neurons. The three stages of 
this proposal--inducing pluripotency, comparing pluripotencies in the reprogrammed cells 
and embryonic stem cells, and differentiating the stem cells--should answer questions 
about ECAT1 and the reprogramming process. It is predicted that ECAT1 should reduce the 
genomic and molecular differences between embryonic stem cells and induced pluripotent 
stem cells. ECAT1's presence should also increase the efficiency of reprogramming as well as 
successful differentiation to other cell types. 
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Introduction 
The search for cures to diseases such as cancer, Parkinson’s, sickle cell anemia, and 
diabetes has been long and difficult. Similarly, a search for solutions to spinal cord injury 
and other debilitating injuries has proven slow and relied on mechanical technology. The 
use of stem cells as a solution has been gaining popularity since their discovery. 
The Discovery of the Stem Cell  
The discovery of the stem cell arose through observations of anomalous 
teratocarcinomas. Scientists discovered that tumor cells have origins in embryonic cells, and 
that cells taken from a tumor, when injected elsewhere, could produce a variety of different 
cell-types.
1-3
 These cells were termed to be stem cells, and research progressed to using cell 
feeder layers to establish what are now known as embryonic carcinoma cells. Discoveries in 
mice preceded discoveries of human embryonic stem cells, beginning with the search for a 
cure for leukemia—the first experiment using stem cells was of bone marrow 
transplantation in irradiated mice, which led to the formation of multilineage colonies and 
to the idea that stem cells could be used as a medicinal technique.
1,2
  
Scientists began work using hematopoietic stem cells—stem cells that give rise to all 
cells of the blood system
2
—and continued to develop the extremely difficult bone marrow 
transplant procedure using these cells. At the same time, research dealt with the properties 
of non-hematopoietic stem cells, specifically focusing on whether carcinomas were the only 
source.  
To aid in this endeavor, the effort focused on enzymes and factors that 
characterized stem cells. In the 1970’s, one such enzyme, alkaline phosphatase, was shown 
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to play a major role in maintaining the main characteristic of pluripotency—the ability of a 
cell to differentiate into most cell types—in a stem cell. In particular, alkaline phosphatase 
was instrumental in uncovering the identities of other pluripotency-related enzymes such as 
SSEA-3, SSEA-4, and NANOG.
4
 The enzymes and markers were all responsible for the ability 
of embryonic stem cells to be grown indefinitely in the pluripotent state under optimal 
conditions, without differentiating.
3
 
Then, in the 1980’s, the first noncarcinomal embryonic stem cells were established 
from mice. This eventually led to the generation of ES cell lines from humans in the late 
1990’s.
1
  
Debating Embryonic Stem Cells 
 With the potential applications for human embryonic stem cells (hESCs) much 
publicized, debate still swirled around the idea of harvesting cells from a human embryo. 
Arguments over whether a human embryo was considered a human life and whether 
harvesting an embryo’s cells was considered stealing murder led to the passing of legislation 
in the United States. While experimentation on human embryos faced major barriers in 
terms of federal funding—President Bill Clinton’s administration prohibited the use of funds 
used in research that led to the destruction of an embryo regardless of its source—stem 
cells faced no such restrictions. 
In 2001, President George W. Bush passed the currently adhered-to legislation 
limiting research to embryonic stem cell lines established only before 2001. In 2006, during 
his second term as president, George W. Bush signed into law the Stem Cell Therapeutic 
Research Act of 2005, which restricted funding for adult stem cell therapies and treatments 
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but not embryonic stem cell research. President Barack Obama in 2009 passed an executive 
order that finally gave federal funding to the study of the established embryonic stem cell 
lines.
5-7
 
The abilities of embryonic stem cells (ESCs)—totipotency and continuous and rapid 
regeneration without differentiating into one of the germ layers—have proved both 
advantageous and harmful. Because of the close relationship with tumors, scientists 
realized that stem cells, if not transplanted into an adult correctly, could induce tumors and 
lead to cancer.
8
 Additionally, they discovered that while ESCs are totipotent, their 
predisposed differentiation potentials could be seen by an adult body’s cells as foreign, 
therefore causing the body to reject the cells.
3
  
Stem cell characteristics 
Stem cells are unique because of their ability to differentiate into any number of 
different cell-types, depending on the type of stem cell.
3
 They can be totipotent, 
pluripotent, or multipotent, etc. (Table 1). Pluripotency of stem cells specifically means the 
ability of the cell to differentiate into all 3 germ layers—ectoderm, endoderm, and 
mesoderm.
6,7
  
Stem cells self-renew rapidly, making them ideal for regenerating undamaged cells 
with the correct genetic makeup in areas where cells have been greatly damaged.
3
 
However, this ability has the great potential to cause not only tumor growth, but malignant 
tumor growth.
8
 These two characteristics are crucial to stem cell medicine, therefore 
scientists have been focusing on finding pluripotent or totipotent cells that can proliferate 
like ESCs. Because of the limitations and safety risks of using embryonic cells in adult bodies, 
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the scientific community decided that using one’s own cells was the best way to reduce the 
risk of immune responses to outside genetic information. 
Table 1. States of potency within cells
6,7
 
Alternative techniques 
A technique called somatic cell nuclear transfer (SCNT) was developed in which ESC 
nuclei were transferred into adult somatic cells whose own nuclei had been removed. The 
experiment proved that the genetic information and tendencies of ESC and early embryonic 
cells were retained in their nuclei, allowing the somatic cell to reprogram and form into a 
blastocyst.
9
 As this technique to induce pluripotency still employed the use of embryonic 
cells, however, scientists kept searching for other methods to obtain ESC characteristics in 
normal adult somatic cells. Another technique that held promise but was quickly discarded 
was the cellular hybridization of somatic cell fusion with an ESC, because of its use of ESCs, 
something scientists did not want to rely on.
9
 
Potency Definition Examples of cells 
Totipotent 
The ability to divide into and produce all 
possible differentiated cells, including 
extraembryonic tissues 
Spores 
Zygotes 
Pluripotent 
The ability to divide into and produce all cells of 
the three germ layers (endoderm, ectoderm, 
mesoderm) 
Embryonic stem cells 
Induced pluripotent stem cells 
Some adult stem cells 
Multipotent 
The ability to divide into and produce cells in a 
closely related family of cells of multiple 
lineages 
Hematopoietic stem cells 
Oligopotent 
The ability to divide into and produce few cells 
of limited types of cell lineages 
Lymphoid stem cells 
Myeloid stem cells 
Unipotent 
The ability to divide into and produce only one 
cell type through self-renewal properties of 
stem cells 
Muscle stem cells 
 10 
 
The SCNT technique spawned an entirely different field of research, that of cloning, 
which led to the eventual cloning of ‘Dolly’ the sheep. However, the cloning experiments 
also demonstrated and helped confirm earlier theories that cells differentiated due to 
epigenetic changes in the cells, and that reversing those epigenetic changes—usually by 
affecting histone wrapping and through methylation and acetylation—could cause a cell to 
dedifferentiate, or return to an undifferentiated state.
10
 
Inducing Pluripotency: the 2006 experiment
11
 
It was not until 2006, when Kazutoshi Takahashi and Shinya Yamanaka published 
their seminal paper and proved the possibility of inducing pluripotency without narrowed in 
on a set of transcriptional factors present in ESCs that could be inserted into somatic cells of 
any stage—they used mouse embryonic fibroblasts and adult tail-tip fibroblasts—to induce 
a pluripotent state. Their findings, which set the stage for stem cell research until today, 
found 4 transcription factors—Oct3/4, Sox2, Klf4, and c-Myc, together known as “OSKM”—
that were necessary to create induced pluripotent stem cells (iPSCs).
10-15
  
Using 24 candidate genes known to be particular to ESCs, Takahashi and Yamanaka 
used retroviral transduction to insert those genes into the fibroblasts and systematically 
eliminated factors until a set of 10 were left. From there, the researchers eliminated more 
factors until only 4 were left. A series of experiments confirmed that these specific factors 
were essential, that fewer factors did not improve the already low efficiency of inducing 
pluripotency. The results, repeated with adult fibroblasts, confirmed that any cell type could 
undergo this method and become an iPSC. When compared to mouse ESCs, their new 
induced pluripotent stem cells were very similar in morphology and phenotype, which 
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proved that their method not only worked, but that their findings of the 4 transcription 
factors were correct as well.
11
 
Oct3/4, Sox2, Klf4, and c-Myc, while researched extensively before 2006, have all 
been the subject of further study, this time to discover the mechanisms of inducing 
pluripotency. Each factor has a specific role in maintaining pluripotency, making each factor 
important. Working in an interdependent capacity, the factors go through an 
autoregulatory feedback look that enables for the maintenance of the ESC pluripotent 
state.
12
 However, studies have confirmed that optimal efficiency for inducing pluripotency is 
obtained through different concentrations of the factors being expressed.
13
  This is due, 
research has shown, to the different roles each factor plays in cells. 
Oct3/4 
Oct3/4 is a factor involved in the maintenance of the self-renewal of pluripotent 
cells and works closely with Sox2 and NANOG, two other transcription factors associated 
with ESCs.
10,14-17
 Oct3/4, otherwise known as Oct3, Oct4, or POU5F1, is primarily expressed 
in germline cells and is specifically involved in the formation of the inner cell mass of 
blastocysts. A tightly regulated factor, Oct3/4 is required in large amounts when inducing a 
cell to the pluripotent state and has the capacity to induce pluripotency on its own, but at 
low efficiency. Without Oct3/4, however, a cell will not become an iPSC.
12-16
 
Sox2 
Sox2, a close cofactor of Oct3/4, is a member of the Sox gene family that exists in 
the epiblast of elongating blastocysts.
16
 While only a small amount of Sox2 is required for 
the pluripotent state,
13
 and while it is even sometimes completely dispensable to 
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reprogramming,
15
 its presence works with Oct3/4 to ensure the cell stays pluripotent. Sox2 
may also be involved in differentiation at a later stage, as certain amounts of Sox2 in a cell 
can lead to trophoblast formation.
18
  
Klf4 
Klf4, a Kruppel-like zinc finger transcription factor, is involved in cell growth 
regulation and differentiation. Klf4 is directly connected to tumor suppressor protein p53, 
which is also involved in regulating the cell cycle. Like Sox2, only small amounts of Klf4 
contribute to increased efficiency of cell reprogramming. One of the main functions of Klf4 
is to suppress p53—which would otherwise prevent NANOG from being activated—and 
lead to differentiation.
14-16,18
  
c-Myc 
The last of the factors, c-Myc, is perhaps the most dispensable. This basic helix-loop-
helix leucine zipper transcription factor has roles in cell growth, differentiation, and 
proliferation. It can block differentiation or block proliferation, depending on the cell type 
and depending on other factors around it. By far the gene with the most binding sites, c-
Myc works with the LIF (leukemia inhibitory factor) signaling pathway that helps maintain 
pluripotency. When Klf4 activates p21, a target for p53, c-Myc can sometimes step in and 
silence p21, therefore keeping the cell in a proliferating state. While not entirely required, 
large quantities of c-Myc prevent iPSCs from apoptosis.
14-16,18
  
While other factors have since been found that can induce pluripotency, OSKM are 
still considered the main and most efficient transcription factors for inducing pluripotency 
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in a cell. These factors also transcend organisms—they are found in murine embryonic stem 
cells as well as human embryonic stem cells (hESCs).  
Inducing Pluripotency: the 2007 human experiment
19
 
The ability to induce pluripotency in human somatic cells was proved in 2007 by 
Takahashi and Yamanaka, just a year after their groundbreaking discovery that 
reprogramming could be induced in mice.
11
 The two scientists reproduced their 2006 
experiment and proved that human iPSCs could be formed from the transduction of OSKM 
into human fibroblasts.
19
 Similar to mouse iPSCs, human iPSCs were morphologically and 
phenotypically similar to hESCs. Some other genes were also found to be in both human and 
murine stem cells (Fig. 1A,B), solidifying the theory that stem cells of any organism are 
similar in genotype. A major difference between human iPSCs and murine iPSCs can be 
found in the expression of these genes, however. The expression of certain genes in human 
iPSCs mirrors those expressed in hESCs, while the expression of genes in murine iPSCs 
differs slightly from mouse ESCs—some factors are less expressed in the iPSCs than in the 
ESCs, and some genes, while known to be present in ESCs, are not expressed at all in iPSCs 
(Fig. 1A), for example the gene ECAT1, the only gene not expressed to some extent in iPS-
MEF4-7. This difference in expression could account for the slight differences observed in 
iPSCs.  
 14 
 
Figure 1. Gene expression of hES cell-marker genes. Comparison of genes tested for and 
expressed in both mice and humans. A RT-PCR analysis of ES marker genes in mouse iPS 
cells, ES cells, and MEFs.
11
 B RT-PCR analysis of ES cell-marker genes in human iPS cells, 
ES cells from cell line H9, human embryonic carcinoma cell line NTERA-2, and HDFs.
19
 
Visit 
http://www.sciencedirect.com/science/article/pii/S00
92867406009767, Figure 3A  
and  
http://www.cell.com/fulltext/S0092-
8674%2807%2901471-7, Figure 2A,  
for access to Figure 1 A and B, respectively. 
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Difficulties with iPSCs 
While induced pluripotent stem cells are very similar to ESCs, it has been found that 
iPSCs still carry traces of their original cell types and are therefore more likely to 
differentiate into certain cell types instead of being able to differentiate into any cell type. 
Supporting this finding is the realization that the genes in ESCs and iPSCs differ in gene 
expression.
20
 The stability of iPSCs has also come under question, as they seem genetically 
unstable.  
Other difficulties include iPSC generation efficiency: the most common method by 
far of retroviral transduction—used by Takahashi and Yamanaka in the initial 
experiments
11,19
—involves using a viral vector to introduce OSKM into a somatic cell. The 
properties of the virus could also induce mutagenesis in the cell and, combined with OSKM 
and the new pluripotent properties of the cell, lead to oncogenesis.
21
 Using a retrovirus 
poses dangers, however, because of the body’s innate immune response to a foreign 
substance—the host cell of the virus, upon identifying the virus, would initiate the sequence 
of events that includes activation of p53 and eventual cell death.
22
 Additionally, the 
retroviral vectors integrate randomly into the host chromosome, leading to leaky 
expression for each cell and making the cells hetereogeneous.
9
 The efficiency of retroviral 
transduction for cellular reprogramming is low, leading to the search for other methods to 
get OSKM into somatic cells.  
 16 
 
Proposal 
 The characteristics of embryonic stem cells as described previously make them the 
ideal to strive towards in iPSC research. Therefore many studies have, to date, found 
epigenetic differences that could explain the genomic imprinting in iPSCs that differentiates 
them from ESCs. If genetic expression differs between the two, it can be assumed that there 
are molecular differences as well. The challenge is to find methods to reduce these 
differences, to make iPSCs more similar to ESCs. A method proposed in this study is adding 
an ESC-associated protein, which would theoretically confer more ESC characteristics on 
iPSCs, whether through the presence of more ESC pluripotency markers, or through a 
greater similarity in gene expression and methylation mapping between iPSCs and ESCs. 
ECAT1 
 One such ESC-associated protein, whose gene was studied in Takahashi and 
Yamanaka’s 2006 experiment, is the relatively unknown ECAT1. Also known as ES Cell-
Associated Transcript 1 or c6orf221, ECAT1 belongs to the ECAT family, which describes any 
factors characterizing pluripotency such as Oct3/4, Sox2, and its fellow ECAT protein, ecat4, 
or NANOG.
23,24
 
It is not known for sure whether each member of the ECAT family has the same roles 
in stem cells. For example, the nonessential NANOG activates transcription of pluripotency 
markers to increase reprogramming,
3,18
 maintains pluripotency for longer in cells with it 
compared to cells without it and thus changing cell morphology
17
, and may even activate 
cancer-pathways, which highlights the thin line between stem cells and tumor cells that 
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poses a risk in stem cell medicine
3
.  ECAT1 differs in one respect: the protein contains an 
atypical KH domain, commonly seen in DPPA5, OOEP, and KDHC1 proteins, all of which are 
absent in rodents
25
. The KH domain is present in nucleic acid-binding proteins and allows for 
binding of RNA as well as RNA recognition
26
.  
Although ECAT1 is present in embryonic stem cells and oocytes, it was not found to 
be expressed in initial reprogramming efforts in murine cells (Fig 1A).
6
 When 
reprogramming was attempted with human somatic cells, the presence of ECAT1 was not 
tested and confirmed. Since the study only tested the possibility of inducing pluripotency 
using OSKM, and given ECAT1’s fellow factor NANOG’s role in maintaining pluripotency, it 
could be assumed that ECAT1’s role—and presence—in inducing pluripotency in human 
cells has yet to be extensively discussed, especially as so little is known about ECAT1. 
Proposed Experiments 
 With research focusing on ways to replicate ESC characteristics when inducing 
pluripotency in somatic cells, this could provide an opportunity to observe ECAT1 in more 
depth by testing its effects on inducing pluripotency. This study therefore aims to look at 
the effects of ECAT1 through the entire iPSC process, from reprogramming to 
differentiation, in three stages:  
1) ECAT1 will be used with the OSKM factors to induce 
pluripotency in adult human fibroblasts using retroviral 
transduction of polycistronic vectors.  
 18 
 
2) The newly-formed hiPSCs will be compared against hESCs for 
any changes suggesting increased similarities between hiPSCs 
and hESCs.  
3) The differentiating ability of the new hiPSCs will be tested by 
differentiating them into spinal motor neurons and analyzed for 
functionality and similarities to existing motor neurons.  
Using tried and true methods of previous studies researching iPSCs, this proposal 
offers a chance to study a relatively unknown factor—ECAT1—and also discover more about 
the differences between hiPSCs and hESCs.  
 19 
 
Materials & Methods 
Stage 1: Retroviral transduction-based reprogramming 
Because of its popular use in stem cell research, retroviral transduction will be used 
as the method to induce pluripotency in adult human fibroblasts. Retroviral transduction 
was first used in the seminal 2006 and 2007 papers that confirmed the possibility of 
creating iPSCs (both murine and human). The efficiency of inducing pluripotency (Table 2) 
using retroviruses, which, along with lentiviruses, are known as integrating viruses, is 
relatively low
27
. However, non-integrating vector viral transduction—using adnoviruses and 
RNA viruses like the Sendai virus
28,29
—as well as nonviral methods—direct protein 
delivering, non-integrating episomal vectors, piggyBac transposition
30
, miRNAs, 
nucleofection, mRNA
31
, minicircle vectors, artificial chromosome vectors
32
, and 
nanoparticles
33
—which could lower the chances of inciting an immune response from 
somatic cells during reprogramming
9
, yield lower reprogramming efficiency. Continuing 
research has shown that efficiency increases with the supplementation of small chemical 
compounds. 
Table 2. Approximate reprogramming efficiencies of human fibroblasts
27
 
Vector Method 
Approximate reprogramming efficiency in human 
fibroblasts 
a
 
Virus 
Retrovirus 
Lentivirus 
Adenovirus 
Sendai virus 
++++ 
+++ 
+ 
++++ 
DNA 
Episomal plasmid 
Transposon 
Minicircle 
+ 
++ 
+ 
RNA RNA +++ 
Protein Cell transparent protein + 
a
+, <0.001%; ++, <0.01%; +++, <0.1%; ++++, >0.1%. 
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In accordance with an experiment performed by Zhang et al
34
, human OSKM fusion 
genes (hOSKM) with 2A sequences separating human cDNA sequences of each 
reprogramming factor will be created (Figure 2A). This gene, along with another gene 
sequence containing human cDNA for ECAT1 only, will be constructed into a vector, 
pMIGR1, with high-expression MSCV (Murine Stem Cell Virus) promoter, which is especially 
used in research with stem cells.
35
 A GFP marker will be cloned downstream of the factors, 
after an IRES sequence, to enable factor tracking during the experiment. Retroviral 293T 
cells will then be transfected with the vectors to create the retrovirus.
34
 One sample of 
5’LTR  MSCV IRES eGFP 3’LTR hECAT1 
Figure 2. pMIGR1 vector designs for retroviral transduction-based cell reprogramming. 
MSCV: Murine Stem Cell Virus promoter. IRES: internal ribosomal entry site. A 
Polycistronic vector with OSKM factors and inserted 2A sequences between
35
 B ECAT1-
containing retroviral vector. ECAT1’s close connections with Oct3/4 and Sox2 suggest 
same promoter would work. 
5’LTR  MSCV IRES eGFP 3’LTR 
hOCT3/
4 
hSOX2 hKLF4 hcMyc 
E2A P2A T2A 
A 
B 
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retrovirus will have only the OKSM sequence vector, while another sample will have both 
the OSKM sequence vector and the ECAT1 sequence vector.  
Confirming pluripotency 
To test the ability to reprogram, human dermal fibroblasts will be infected with the 
retroviral T293 cells. Adult human fibroblasts have been extensively used in stem cell 
studies
37,38
, making them the ideal candidates to test the effects of ECAT1. The cells will be 
plated and grown in medium containing sodium butyrate, SB431542, and PD0325901,
34
 
which have been shown to increas the efficiency of reprogramming somatic cells, and which 
have supplemented the findings of researchers that certain chemicals and other growth 
factors can increase reprogramming efficiency.
9
  
A series of tests will confirm progress of reprogramming. To confirm transduction of 
the factors into the fibroblasts, the cells will be studied for colony growth, GFP expression, 
as well as cell morphology. The main success of this stage will be shown through formation 
of cells, indicating that the retrovirus integrated into the cells instead of inciting an immune 
response and cell death. The hiPSCs will be tested against human adult dermal fibroblasts as 
well as a set of 6 hESC lines (Table 3), which have been used as comparisons to iPSC lines in 
different experiments
38
. The multiple hESC lines should provide more information to be able 
to compare the hiPSCs to the different variables within hESC lines themselves. RT-PCR 
analysis of the cells should molecularly confirm presence and expression of the 
reprogramming factors in the cells, and comparison of factor levels in hiPSCS and hESCs will 
further confirm successful reprogramming. 
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Table 3. Cells used in comparing pluripotency and other cell characteristics
38 
Cell Type Variation Sample 
Somatic cell HDF Control 
hiPS 
hiPS 
OSKM 
OSKM + ECAT1 
Control 
Test 
hESC
 
HuES-3
39 
HuES-6
39 
HuES-9
39 
HuES-13
39 
HuES-3 hb9:GFP
40 
RUES1
41 
Control 
Stage 2: hiPSCs vs hESCs 
The major component of this research proposal is studying the comparison between 
the induced pluripotent stem cells and human embryonic stem cells, to see how similar the 
two cell types are. Ideally, the newly-formed hiPSCs mirror hESCs exactly, in morphology, 
cell marker expression, gene expression, and ability to differentiate into absolutely any of 
over 200 different cell types
12
. Induced pluripotent stem cells retain an ESC-like rounded 
shape, especially in the late passages of the cell
20,42
 and can therefore be one of the first 
indications of pluripotency. In fact, the cell becomes is more stem cell-like during the late 
passages than in the early passages, suggesting that the cell is constantly changing during 
the reprogramming.
20
 Therefore, rounded cell morphology in late passage hiPSCs should 
indicate pluripotency of the reprogrammed cells. The major comparisons will be done in the 
forms of two studies: a molecular study and a genomic study. 
Molecular comparisons 
The markers of pluripotency have been identified through certain hESC surface 
markers as well as the increased presence of certain enzymes. Expression of alkaline 
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phosphatase, using an alkaline phosphatase assay, will be found. Additionally, 
immunostaining will be performed not only for the reprogramming factors transfected into 
the cells—Oct3/4, Sox2, Klf4, c-Myc, and ECAT1—but also pluripotency factors such as 
NANOG, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81, all of which are present in hESCs
4
. The 
most common immunostaining analysis method used in stem cell research is flow 
cytometry, however Western blotting will also be used to confirm expression of OSKM and 
ECAT1. These tests will be performed on the human dermal fibroblasts as well as the hESC 
lines, to create comparisons.  
Genomic comparisons 
While the analysis of cell surface markers and pluripotency factors in the newly 
reprogrammed hiPSC cells with ECAT1 can help, a deeper analysis of the differences in 
genome between the hiPSCs and hESCs can help gain a deeper understanding for ECAT1’s 
effects on somatic cells and therefore a better understanding of its function in embryonic 
stem cells. There are approximately 3,947 genes out of 17,620 that are significantly 
different between all established hiPSC and hESC lines
20
, making it the goal of this study to 
see if that difference can be decreased with the presence of ECAT1.  
To each cell sample, a genome-scale bisulfate sequencing, set of microarray assays, 
and high-throughput transcript counting differentiation assay that made use of marker 
genes in embryoid bodies.
42
  
The bisulfate sequencing will map each DNA methylation site, allowing for the 
comparisons of number and location of CpG dinucleotides across all cell samples. This is 
important because reprogramming cells to pluripotency has been shown to be 
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accompanied by hypomethylation and changes to primarily pluripotency-related promoters 
that are typical for ESCs.
43,44
 Focus on genes such as DNA methyltransferase DNMT3B, 
antioxidant CAT, developmental regulator PAX6, and macrophage/granulocyte surface 
marker CD14 should give better ideas of changes, as well. 
The microarrays performed on each sample (Table 3) should give expression of 
genes that can then be compared with each other and hopefully reveal fewer differences in 
gene expression. The differentiation assay would look at RNA expression of genes 
specifically associated with stem cells—those having to do with pluripotency, 
differentiation, and cell state monitoring, etc. Specifically focusing on the reprogramming 
pathway and genes associated with it in this assay will allow for a closer look at which 
reprogramming-specific genes are affected during the course of the pathway.
44
 Statistical 
analyses can help quantify patterns of behavior as well.  
Stage 3: Differentiation 
 The final set of experiments testing the effects of ECAT1 on pluripotency will look at 
differentiation of the hiPSCS and hESCs and compare the differentiated, newly-somatic cells 
to their originally somatic cell counterparts. For this part of the experiment, the stem cells 
will all be differentiated into spinal motor neurons, a type of cells that have proven difficult 
to extract to study in vitro when diseased. hiPSCs and hESCS will be converted into 
embryoid bodies, clusters of pluripotent stem cells that form in preparation for 
differentiation using a typical embryoid body formation assay. These embryoid bodies can 
then be made to differentiate into the neurons using specific growth factors and involving 
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the use of retinoic acid and the sonic hedgehog pathway in a common method of 
differentiating pluripotent stem cells to neural cells.
38
 
Confirming Differentiation 
 Confirmation of differentiation can be found through comparing morphologies of 
the differentiated cells to existing motor neurons. Expression of TUJ1 and motor neuron 
marker ISLET ½ (ISL) further confirms the exact identity of the newly differentiated cells. 
Immunostaining for the presence of motor neuron-specific factors HB9, acetylcholine 
synthesizer ChAT, neural marker NCAM along with the neural precursor cells undoubtedly 
generated from differentiation because of the low generation efficiency rate, and mRNA 
encoding for markers like CHT1, can help confirm the accurate differentiation of the hiPSCs 
and hESCs. Proof of proper motor neuron function can come with Ki67 immunostaining to 
measure cycling rate of activity, as well as a Ca
2+
 assay that rigorously enhanced the 
activities of the neuron during spontaneous activity as well as forced depolarization of the 
membrane to open the gated Ca
2+
 channels. Immunostaining for ISL would confirm the 
positive identity of the cells as spinal motor neurons.
38
 Electrophysiologial recordings of 
cells made under standard and stressful conditions could help when comparing their activity 
to existing spinal motor neurons, to look for similar data.   
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Predicted Results 
 The ideal results for the three stages of this research proposal’s study show ECAT1 
having a positive effect on reprogramming, on maintaining pluripotency, and on 
differentiation. Because of ECAT1’s role in hESCs as that of an RNA binder, and because of 
its visible detection in the cells before being silenced, when the cell begins developing and 
differentiating, it can be assumed that ECAT1 helps maintain pluripotency. The presence of 
ECAT1 should, if not actively change something in a reprogramming cell, at least influence 
the unwinding of parts of DNA containing more pluripotency genes. ECAT1’s tendency to 
bind nucleic acids would come in handy here, as it could manipulate the genome 
Stage 1: Pluripotency 
With or without ECAT1, the presence of the OSKM factors, coupled with the 
chemicals sodium butyrate, SB431542, and PD0325901,
34
 which allow for more effective 
reprogramming, should result in a yield of cells with pluripotent characters. Chief among 
these is morphology. Embryonic stem cells are smooth and round-shaped, whereas somatic 
cells tend to have more texture to their shapes. It would be easy to see a change in cell 
shape. Positive identification of the expression of the reprogramming factors would confirm 
the success of reprogramming. With ECAT1 present, it is the hope that more pluripotency 
factors are influenced into becoming active, thereby raising the chances of an induced 
pluripotent stem cell’s staying alive and healthy.  
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Stage 2: Molecular Comparison 
 Embryonic stem cells have high levels of alkaline phosphatase to maintain 
pluripotency, in addition to having high levels of NANOG, Oct3/4, Sox2, SSEA-3, SSEA-4, 
TRA-1-60, TRA-1-80, and a host of other ESC markers. Immunostaining and then flow 
cytometry and Western Blotting should show the presence of all these in not only the 
OSKM-induced PSCs, but also the OSKM+ECAT-induced PSCs, as well as the established hESC 
lines. Little to none of these markers should be detected in the adult human fibroblasts 
used for reprogramming in the first place. As mentioned before, ECAT1’s presence in the 
cell may induce a positive activation of other pluripotency genes kept tightly wrapped, and 
so it is the hope that ECAT1 will be visible in analyses of immunostainings, and that 
expression of pluripotency markers is higher. 
Stage 2: Genomic Comparison 
 ECAT1’s role of manipulating nucleic acid binding sites may prove helpful in 
unraveling the cell’s genome to allow expression of the previously-hidden pluripotency 
genes. DNA methylation would be very different than before, and the approximately 4,000-
difference in gene expression between hiPSCs and hESCs would shrink. Because ECAT1 has 
not previously been shown to be expressed naturally in cells more developed than 
embryonic stem cells, this may have a dampening effect on the effects of ECAT1, which still 
must be studied further for more information about its role in pluripotency. The counting 
assay would allow a look at what reprogramming-specific genes are still inactivated in the 
hiPSCs, which would pave the way for future studies looking into how to unlock those 
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genes. Hopefully, again, ECAT1 has made a difference so that less genes need to be worked 
on being activated.  
Stage 3: Differentiation 
 Differentiation is a very common procedure, as the human body’s cells are more 
likely to do that than to reprogram themselves. Hence, the differentiated cell yield should 
be of a good size. The presence of ECAT1 may have more of an effect in helping sort the 
genes to make the newly differentiated spinal motor neurons more efficient in their activity. 
The series of rigorous testing is meant to see if the new cells can hold up to their more 
established counterparts. Assuming that differentiation does not accidentally turn off any 
crucial genes, the new spinal motor neurons should function in exactly the same ways.  
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Significance & Conclusion 
The field of stem cell research is growing because of interest in using stem cells to cure 
diseases and heal injuries. Embryonic stem cells, because of the controversy surrounding 
them—and subsequently the difficulties in acquiring samples of the existing aging cell 
lines—can only be used in limited capacities. The development and study of induced 
pluripotent stem cells has allowed the field to progress closer to therapeutical applications 
of stem cells, yet there are still many challenges. iPSCs and ESCs are still remarkable 
different in pluripotency character, and it has been shown on occasion that neither type of 
stem cell can completely differentiate into a fully-functioning somatic cell. The efforts to 
create stem cells that are identical to embryonic stem cells have proved and disproved a 
number of methods, chemicals, factors, and conditions thought to improve pluripotency in 
iPSCs. This proposal is one such research attempt to prove or disprove ECAT1’s role in 
pluripotency. Since little is known about ECAT1, this research also attempts to characterize 
ECAT1’s forced presence in iPSCs. With this study, it may just be that the key to unlocking all 
of an iPSC’s pluripotent potential has been found. It is equally likely that ECAT1 has no 
effect, or even a negative effect, on reprogramming and especially differentiation. The goal 
of this research is to find out which of those effects is accurate, so that scientists can either 
continue researching ECAT1, or know there is one less component to look at in the quest to 
bring stem cell medicine to reality. 
 
 
 
 30 
 
References 
LiteratureCited 
1
 Solter, Davor. 2006. From teratocarcinomas to embryonic stem cells and beyond: a history 
of embryonic stem cell research. Nature 7: 319-327.
 
2
 Boisset, J-C., Robin, C. 2011. On the origin of hematopoietic stem cells: Progress and 
controversy. Stem Cell Res 8: 1-13. 
 3
 Ha, H-Y., Jang, S-H., Jung, J-W. 2011. The use of pluripotent stem cell for personalized cell 
therapies against neurological disorders. J Biomed & Biotech 2011: 1-7. 
4-6
 see web articles  
7
 Gardner, R.L. 2002. Stem cells: potency, plasticity and public perception. J Anat 200(3): 
277-282. 
8
 Hibaoui, Y., Jaconi, M., Chicha, L., Bergstrom-Tengzelius, R., Sailani, M.R., Pelte, M.F., 
Dahoun, S., Mitsiadis, T.A., Tohonen, V., Bouillaguet, S., Antonarakis, S.E., Kere, J. 2011. 
NANOG priming before full reprogramming may generate germ cell tumours. Eur Cells and 
Mats 22: 258-274. 
9
 Dey, D., Evans, G.R.D. 2011. Generation of induced pluripotent stem (iPS) cells by nuclear 
reprogramming. Stem Cells Int 2011: 1-11. 
 
10
 Na, J., Plews, J., Li, J., Wongtrakoongate, P., Tuuri, T., Feki, A., Andrews, P., Unger, C. 2010. 
Molecular mechanisms of pluripotency and reprogramming. Stem Cell Res 1(33): 1-8. 
11
 Takahashi, K., Yamanaka, S. 2006. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676. 
12
 Greenow K, Clarke AR. 2012. Controlling the stem cell compartment and regeneration in 
vivo: the role of pluripotency pathways. Physiol Rev 92(1): 75-99. 
13
 Tiemann, U., Sgodda, M., Warlich, E., Ballmaier, M., Scholer, H.R., Schambach, A., Cantz, 
T. 2011. Optimal reprogramming factor stoichiometry increases colony numbers and affects 
molecular characteristics of murine induced pluripotent stem cells. Cytometry Part A 79A: 
426-435. 
14
 Lewitzky, M., Yamanaka, S. 2007. Reprogramming somatic cells towards pluripotency by 
defined factors. Curr Op in Biotech 18: 467-473. 
 31 
 
15
 Takahashi, K. 2010. Direct reprogramming 101. Dev, Growth & Diff 52: 319-333. 
16
 Guo, J., Li, Z., Feng, Y. 2009. Expression and activation of the reprogramming transcription 
factors. Biochem & Biophys Res Comm 390: 1081-1086. 
17
 Bartova, E., Sustackova, G., Stixova, L., Kozubek, S., Legartova, S., Foltankova, V. 2011. 
Recruitment of Oct4 protein to UV-damaged chromatin in embryonic stem cells. PLoS ONE 
6(12): 1-13. 
18
 Ralston, A., Rossant, J. 2010. The genetics of induced pluripotency. Reproduction 139: 35-
44. 
19
 Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S. 
2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. 
Cell 131: 861-872. 
20
 Chin, M.H., Mason, M.J., Xie, W., Volinia, S., inger, M., Peterson, C., Ambartsumyan, G., 
Aimiuwu, A., Richter, L., Zhang, J., Khvorostov, I., Ott, V., Grunstein, M., Lavon, N., 
Benvenisty, N., Croce, C.M., Clark, A.T., Baxter, T., Pyle, A.D., Teitell, M.A., Pelegrini, M., 
Plath, K., Lowry, W.E. 2009. Induced pluripotent stem cells and embryonic stem cells are 
distinguished by gene expression signatures. Cell Stem Cell 5: 111-123. 
21
 Okita, K., Ichisaka, T., Yamanaka, S. 2007. Generation of germ-line competent induced 
pluripotent stem cells. Nature 448: 313-317. 
22
 Mah, N., Wang, Y., Liao, M-C., Prigione, A., Jozefczuk, J., Lichtner, B., Wolfrum, K., 
Haltmeier, M., Flottmann, M., Schaefer, M., Hahn, A., Mrowka, R., Klipp, E., Andrade-
Navarro, M.A., Adjaye, J. 2011. Molecular insights into reprogramming-initiation events 
mediated by the OSKM gene regulatory network. PLoS ONE 6(8): 1-17. 
23
 Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., 
Maeda, M., Yamanaka, S. 2003. The homeoprotein Nanog is required for maintenance of 
pluripotency in mouse epiblast and ES cells. Cell 113: 631-642. 
24
 Imamura, M., Miura, K., Iwabuchi, K., Ichisaka, T., Nakagawa, M., Lee, J., Kanatsu-
Shinohara, M., Shinohara, T., Yamanaka, S. 2006. Transcriptional repression and DNA 
hypermethylation of a small set of ES cell marker genes in male germline stem cells. BMC 
Dev Biol 6:34 
25
 Pierre, A., Gautier, M., Callebaut, I., Bontoux, M., Jeanpierre, E., Pontarotti, P., Monget, P. 
2007. Atypical structure and phylogenomic evolution of the new eutherian-associated 
oocyte- and embryo-expressed KDHCI/DPPA5/ECAT1/OOEP gene family. Genomics 90(5): 
583-594. 
26
 see web articles 
 32 
 
27
 Okita, K., Yamanaka, S. 2011. Induced pluripotent stem cells: opportunities and 
challenges. Phil. Trans. R. Soc. B 366(1575): 2198-2207. 
28
 Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M. 2009. Efficient induction of 
transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA 
virus that does not integrate into the host genome. Proc Jap Acad S B 85(8): 348-362. 
 
29
 Ban, H., Nishishita, N., Fusaki, N., Tabata, T., Saeki, K., Shikamura, M., Takada, N., Inoue, 
M., Hasegawa, M., Kawamata, S., Nishikawa, S-I. 2011. Efficient generation of transgene-
free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus 
vectors. PNAS 108(34): 14234-14239. 
 
30
 Yusa, K., Rad, R., Takeda, J., Bradley, A. 2009. Generation of transgene-free induced 
pluripotent mouse stem cells by the piggyBac transposon. Nat Meth 6(5): 363-369. 
31
 Travernier, G., Wolfrum, K., Demeester, J., De Smedt, S.C., Adjaye, J., Rejman, J. 2011. 
Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral 
transfection with in vitro-derived mRNAs encoding Oct4, Sox2, Klf4 and cMyc. Biomat 3: 
412-417. 
 
32
 Hiratsuka, M., Uno, N., Ueda, K., Kurosaki, H., Imaoka, N., Kazuki, K., Ueno, E., Akakura, Y., 
Katoh, M., Osaki, M., Kazuki, Y., Nakagawa, M., Yamanaka, S., Oshimura, M. 2011. 
Integration-Free iPS Cells Engineered Using Human Artificial Chromosome Vectors. PLoS 
ONE 6(10): 1-14. 
 
33
 Lee, CH, Kim, J-H, Lee, HJ, Jeon, K. Lim, HJ, Choi, H., Lee, E-R, Park, SH, Park, S-Y, Hong, S., 
Kim, S., Cho, S-G. 2011. The generation of iPS cells using non-viral magnetic nanoparticle 
based transfection. Biomaterials 32(28): 6683-6691. 
 
34
 Zhang Z, Gao Y, Gordon A, Wang ZZ, Qian Z, Wu W. 2011. Efficient generation of fully 
reprogrammed human iPS cells via polycistronic retroviral vector and a new cocktail of 
chemical compounds. PLoS ONE 6(10): e26592. 
35
 see web articles 
 
36
 Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, Jaenisch R. 2009. 
Reprogramming of murine and human somatic cells using a single polycistronic vector. 
PNAS 106(1): 157-162. 
37
 Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchieu, J., Sridharan, R., Clark, A.T., 
Plath, K. 2008. Generation of human induced pluripotent stem cells from dermal fibroblasts. 
PNAS 105(8): 2883-2888. 
 33 
 
38
 Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, 
Kahler DJ, Yamaki M, Davidow L, Rodolfa CT, Dimos JT, Mikkilineni S, MacDermott AB, Woolf 
CJ, Henderson CE, Wichterle H, Eggan K. 2011. A functionally characterized test set of 
human induced pluripotent stem cells. Nat Biotech 29: 279–286. 
39
 Cowan, C.A, Klimanskaya, I., McMahon, J., Atienza, J., Witmyer, J., Zucker, J.P., Wang, S., 
Morton, C.C., McMahon, A.P., Powers, D., Melton, D.A. 2004. Derivation of embryonic stem-
cell lines from human blastocysts. N Engl J Med 350: 1353–1356. 
40
 Di Giorgio, F.P., Boulting, G.L., Bobrowicz, S., Eggan, K.C. 2008. Human embryonic stem 
cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-
causing mutation. Cell Stem Cell 3: 637–648. 
41
 James, D., Noggle, S.A., Swigut, T., Brivanlou, A.H. 2006. Contribution of human 
embryonic stem cells to mouse blastocysts. Dev Biol 295: 90–102. 
42
 Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, Ziller M, Croft GF, Amoroso MW, 
Oakley DH, Gnirke A, Eggan K, Meissner A. 2011. Reference maps of human ES and iPS cell variation 
enable high-throughput characterization of pluripotent cell lines. Cell 144(3): 439-452. 
43
 Mattout, A., Biran, A., Meshorer, E. 2011. Global epigenetic changes during somatic cell 
reprogramming to iPS cells. J Mol Cell Biol 3: 341-350. 
44
 Koche, R.P., Smith, Z.D., Adli, M., Gu,H., Ku, M., Gnirke, A., Bernstein, B.E., Meissner, A. 
2011. Reprogramming factor expression initiates widespread targeted chromatin 
remodeling. Cell Stem Cell 8(1): 96-105. 
45
 Karumbayaram, S., Novitch, B.G., Patterson, M., Umbach, J.A., Richter, L., Lindgren, A., 
Conway, A.E., Clark, A.T., Goldman, S.A., Plath, K., Wiedau-pazos, M., Kornblum, H.I., Lowry, 
W.E. 2009. Directed differentiation of human-induced pluripotent stem cells generates 
active motor neurons. Stem Cells 27(4): 806-811 
 34 
 
Web Articles 
4
 stemcells.nih.gov/info/scireport/appendixe, 2009. Appendix E: Stem Cell Markers. Stem 
Cell Information. National Institutes of Health, U.S. Department of Health and Human 
Services. 
5
 en.wikipedia.org/wiki/stem_cell_controversy. Stated Views of Groups in United States on 
Stem Cell Research. Wikipeda.org. 
6
 http://www.medicalnewstoday.com/info/stem_cell. Potency, What are Stem Cells? 
Medical News Today, online. 
26
 en.wikipedia.org/wiki/KH_domain. KH Domain. Wikipedia.org. 
35
 http://www.systembio.com/lentiviral-technology/expression-vectors/cdna/overview, 
2012. Stable overexpression with cDNA lentivectors, promoters descriptions. System 
Biosciences. 
